Figure S6 from The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition
Year: 2023
Type: other
Abstract: Sensitivity of BRCA1-deficient RPE cells with acquired olaparib resistance to prexasertib and lack of effect of monotherapy pre-treatment on the synergistic cytotoxicity between prexasertib and olaparib in TOV112D cells
Authors: Kalindi Parmar, Bose S. Kochupurakkal, Jean-Bernard Lazaro, Zhigang C. Wang, Sangeetha Palakurthi, Paul T. Kirschmeier, Chunyu Yang, Larissa A. Sambel, Anniina Färkkilä, Elizaveta Reznichenko, Hunter D. Reavis, Connor E. Dunn, Lee Zou, Khanh T. Do, Panagiotis A. Konstantinopoulos, Ursula A. Matulonis, Joyce F. Liu, Alan D. D'Andrea, Geoffrey I. Shapiro
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361935266